GT Biopharma (GTBP) Operating Income (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Operating Income of -$2.8 million for Q1 2026, down 47.41% year-over-year from -$5.4 million in Q1 2025, and up 49.1% quarter-over-quarter from -$5.6 million in Q4 2025.
GT Biopharma (GTBP) Operating Income (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Operating Income for 17 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 47.41% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$13.3 million (down 1.01% YoY), while the FY2025 annual figure was -$12.4 million, up 13.52% from the prior year.
- Operating Income improved to -$2.8 million in Q1 2026 per GTBP's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.5 million in Q2 2025 and bottomed at -$7.0 million in Q3 2022.
- Historically, Operating Income has averaged -$3.8 million across 5 years, with a median of -$3.6 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income soared 81.24% — and 2025, when it plunged 48.68%.
- GT Biopharma's Operating Income stood at -$5.8 million in 2022, then jumped by 45.17% to -$3.2 million in 2023, then retreated by 18.78% to -$3.8 million in 2024, then tumbled by 48.68% to -$5.6 million in 2025, then surged by 49.1% to -$2.8 million in 2026.
- Business Quant data shows GTBP's Operating Income at -$2.8 million in Q1 2026, -$5.6 million in Q4 2025, and -$3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | -2.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.85 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -1.51 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Dec 31, 2024 | -3.76 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | -3.17 Mn |
| Sep 30, 2023 | -3.12 Mn |
| Jun 30, 2023 | -3.62 Mn |
| Mar 31, 2023 | -3.67 Mn |
| Dec 31, 2022 | -5.78 Mn |
| Sep 30, 2022 | -7.02 Mn |
| Jun 30, 2022 | -3.01 Mn |
| Mar 31, 2022 | -5.44 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -5.95 Mn |
| Jun 30, 2021 | -4.38 Mn |